Incidence of transfusion-related adverse reactions per patient reflects the potential risk of transfusion therapy in Japan

American Journal of Clinical Pathology

Volumn 140, Issue 2, 2013, Pages 219-224

  Kato, Hidefumi ^a   Uruma, Motoaki ^a   Okuyama, Yoshiki ^b   Fujita, Hiroshi ^c   Handa, Makoto ^d   Tomiyama, Yoshiaki ^e   Shimodaira, Shigetaka ^f   Kurata, Yoshiyuki ^g   Takamoto, Shigeru ^a,h  

^a AICHI MEDICAL UNIVERSITY   (Japan)

^b TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^c TOKYO METROPOLITAN BOKUTOH HOSPITAL   (Japan)

^d KEIO UNIVERSITY   (Japan)

^e OSAKA UNIVERSITY HOSPITAL   (Japan)

^f SHINSHU UNIVERSITY HOSPITAL   (Japan)

^g International Buddhist University   (Japan)

^h Japanese Red Cross Hokkaido Block Blood Center   (Japan)

Author keywords

Adverse reactions; Hemovigilance; Per transfused patient basis; Transfusion practices

Indexed keywords

FRESH FROZEN PLASMA; THROMBOCYTE CONCENTRATE;

ARTICLE; BACKACHE; BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; CHILL; ERYTHROCYTE; FEVER; HEADACHE; HUMAN; HYPERTENSION; HYPOTENSION; INCIDENCE; JAPAN; MAJOR CLINICAL STUDY; NAUSEA AND VOMITING; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PRURITUS; RASH; RESPIRATORY DISTRESS; RETROSPECTIVE STUDY; RIGOR; TACHYCARDIA; THORAX PAIN; TRANSFUSION ASSOCIATED CIRCULATORY OVERLAOD; TRANSFUSION RELATED ACUTE LUNG INJURY; TRANSFUSION TRANSMITTED INFECTION; URTICARIA;

ADVERSE REACTIONS; HEMOVIGILANCE; PER TRANSFUSED PATIENT BASIS; TRANSFUSION PRACTICES;

BLOOD TRANSFUSION; FEVER; HUMANS; HYPERSENSITIVITY; INCIDENCE; JAPAN; NAUSEA; RETROSPECTIVE STUDIES;

EID: 84881218335     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP6SBPOX0UWHEK     Document Type: Article

References (18)

1. Dodd RY. Current risk for transfusion transmitted infections. Curr Opin Hematol. 2007;14:671-676.
2. Klein HG, Lipton KS. Noninfectious serious hazards of transfusion. AABB Association Bulletin 01-4. 2001. http:// www.aabb.org/resources/publications/ bullentins/Pages/ab01-4. aspx.
3. US Food and Drug Administration. Fatalities Reported to FDA Following Blood Collection and Transfusion: Annual Summary for Fiscal Year 2010. Rockville, MD: US Food and Drug Administration, Center for Biologics Evaluation & Research. 2011. http://www.fda.gov/downloads/ BiologicsBloodVaccines/ SafetyAvailability/ReporaProblem/ TransfusionDonationFatalities/UCM254860.pdf.
4. de Vries RRP, Faber JC, Strengers PF; Board of the International Haemovigilance Network. Haemovigilance: an effective tool for improving transfusion practice. Vox Sang. 2011;100:60-67.
5. Andreu G, Morel P, Forestier F, et al. Hemovigilance network in France: organization and analysis of immediate transfusion incident reports from 1994 to 1998. Transfusion. 2002;42:1356-1364.
6. Stainsby D, Jones H, Asher D, et al; SHOT Steering Group. Serious hazards of transfusion: a decade of hemovigilance in the UK. Transfusion Med Rev. 2006;20:273-282.
7. Directive 2002/98 of the European Parliament and the Council of Europe, 27 January 2003, Official Gazette of the European Union L 33/30 of 08/02/2003. http://ec.europa.eu/ health/files/eudralex/vol-1/dir-2002-98/dir-2002-98-en.pdf. Accessed June 17, 2013.
8. Strong DM, AuBuchon J, Whitaker B, et al. Biovigilance initiatives. ISBT Sci Ser. 2008;3:77-84.
9. Siegenthaler MA, Schneider P, Vu DH, et al. Haemovigilance in a general university hospital: need for a more comprehensive classification and a codification of transfusion-related events. Vox Sang. 2005;88:22-30.
10. Giampaolo A, Piccinini V, Catalano L, et al. The first data from the haemovigilance system in Italy. Blood Transfus. 2007;5:66-74.
11. Popovsky MA. Transfusion Reactions. 2nd ed. Bethesda, MD: American Association of Blood Banks Press; 2001.
12. Public Health Agency of Canada. Transfusion transmitted injuries. 2004. http://www.phac-aspc.gc.ca/hcai-iamss/tti-it/.
13. Osselaer JC, Cazenave JP, Lambermont M, et al. An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment. Vox Sang. 2008;94:315-323.
14. Tobian AAR, King KE, Ness PM. Transfusion premedications: a growing practice not based on evidence. Transfusion. 2007;47:1089-1096.
15. Heddle NM. Pathophysiology of febrile nonhemolytic transfusion reactions. Curr Opin Hematol. 1999;6:420-426.
16. Heddle NM, Klama L, Meyer R, et al. A randomized controlled trial comparing plasma removal with white cell reduction to prevent reactions to platelets. Transfusion. 1999;39:231-238.
17. Paglino JC, Pomper GJ, Fisch GS, et al. Reduction of febrile but not allergic reactions to RBCs and platelets after conversion to universal prestorage leukoreduction. Transfusion. 2004;44:16-24.
18. Seftel MD, Growe GH, Petraszko T, et al. Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness. Blood. 2004;103:333-339.